Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

BACKGROUND: As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been established for renal cancer and gastrointestinal stromal tumors. In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but l...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:BMC Cancer
Κύριοι συγγραφείς: Moehler, Markus, Gepfner-Tuma, Irina, Maderer, Annett, Thuss-Patience, Peter C., Ruessel, Joern, Hegewisch-Becker, Susanna, Wilke, Hansjochen, Al-Batran, Salah-Eddin, Rafiyan, Mohammad-Reza, Weißinger, Florian, Schmoll, Hans-Joachim, Kullmann, Frank, von Weikersthal, Ludwig Fischer, Siveke, Jens T., Weusmann, Jens, Kanzler, Stephan, Schimanski, Carl Christoph, Otte, Melanie, Schollenberger, Lukas, Koenig, Jochem, Galle, Peter R.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BioMed Central 2016
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006426/
https://ncbi.nlm.nih.gov/pubmed/27582078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2736-9
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια